Page 65 - TI Journal 18-1
P. 65

USE OF PiB FOR PET IMAGING OF AD                          59



          39.  Nelissen, N.; Vandenbulcke, M.; Fannes, K.;   Hoge, J. A.; Ziolko, S. K.; Holt, D. P.; Meltzer, C.
             Verbruggen, A.; Peeters, R.; Dupont, P.; Van   C.; Dekosky, S. T.; Mathis, C. A. Kinetic mod-
              Laere, K.; Bormans, G.; Vandenberghe, R. Abeta   eling of amyloid binding in humans using PET
              amyloid deposition in the language system and   imaging and Pittsburgh Compound-B. J. Cereb.
              how the brain responds. Brain 130(Pt 8):2055-  Blood Flow Metab. 25:1528–1547; 2005.
              2069; 2007.                              45.  Price, J. C.; Ziolko, S. K.; Weissfeld, L. A.; Klunk,
          40.  Nilsberth, C.; Westlind-Danielsson, A.; Eckman,   W. E.; Lopresti, B. J.; Hoge, J. A.; Lu, X. L.; Bi, W.
              C. B.; Condron, M. M.; Axelman, K.; Forsell, C.;   Z.; Meltzer, C. C.; Tsopelas, N; DeKosky, S.T.;
              Stenh, C.; Luthman, J.; Teplow, D. B.; Younkin,   Mathis, C.A. FDG and PIBPET imaging in
              S. G.; Näslund, J.; Lannfelt, L. The ‘Arctic’ APP   Alzheimer’s disease and mild cognitive impair-
              mutation (E693G) causes Alzheimer’s disease   ment. Neuropsychopharmacology 30:S225-S225;
              by enhanced Abeta protofibril formation. Nat.   2005.
              Neurosci. 4(9):887-893; 2001.            46.  Reiman, E. M.; Chen, K.; Liu, X.; Bandy, D.; Yu,
          41.  Ossenkoppele, R.; Jansen, W. J.; Rabinovici, G.   M.; Lee, W.; Ayutyanont, N.; Keppler, J.; Reeder,
              D.; Knol, D. L.; van der Flier, W. M.; van Berckel,   S. A.; Langbaum, J. B. S.; Alexander, G.E.; Klunk,
              B. N.; Scheltens, P.; Visser, P. J.; Amyloid, P. E. T.   W.E.; Mathis, C.A.; Price, J.C.; Aizenstein, H.J.;
              S. G.; Verfaillie, S. C.; Zwan, M.D.; Adriaanse,   DeKosky, S.T.; Caselli, R.J. Fibrillar amyloid-beta
              S.M.; Lammertsma, A.A.; Barkhof, F.; Jagust,   burden in cognitively normal people at 3 levels
              W.J.; Miller, B.L.; Rosen, H.J.; Landau, S.M.;   of genetic risk for Alzheimer’s disease. Proc. Natl.
             Villemagne, V.L.; Rowe, C.C.; Lee, D.Y.; Na,   Acad. Sci. U.S.A. 106(16):6820-6825; 2009.
              D.L.; Seo, S.W.; Sarazin, M.; Roe, C.M.; Sabri,   47.  Remes, A. M.; Finnila, S.; Mononen, H.;
              O.; Barthel, H.; Koglin, N.; Hodges, J.; Leyton,   Tuominen, H.; Takalo, R.; Herva, R.; Majamaa,
              C.E.; Vandenberghe, R.; van Laere, K.; Drzezga,   K. Hereditary dementia with intracerebral
             A.; Forster, S.; Grimmer, T.; Sánchez-Juan, P.;   hemorrhages and cerebral amyloid angiopathy.
              Carril, J.M.; Mok, V.; Camus, V.; Klunk, W.E.;   Neurology 63(2):234-240; 2004.
              Cohen, A.D.; Meyer, P.T.; Hellwig, S.; Newberg,   48.  Remes, A. M.; Laru, L.; Tuominen, H.; Aalto,
             A.; Frderiksen, K.S.; Fleisher, A.S.; Mintun, M.A.;   S.; Kemppainen, N.; Mononen, H.; Någen, K.;
              Wolk, D.A.; Nordberg, A.; Rinne, J.O.; Chételat,   Parkkola, R.; Rinne, J. O. 11C-PIB-PET amyloid
              G.; Lleo, A.; Blesa, R.; Fortea, J.; Madsen, K.;   imaging in patients with APP locus duplication.
              Rodrigue, K.M.; Brooks, D.J. Prevalence of amy-  Arch. Neurol. 65(4):540-544; 2007.
              loid PET positivity in dementia syndromes: a   49.  Resnick, S. M.; Sojkova, J. Amyloid imaging
              meta-analysis. JAMA 313(19):1939-1949; 2015.  and memory change for prediction of cognitive
          42.  Petersen, R. C.; Wiste, H. J.; Weigand, S. D.; Rocca,   impairment. Alzheimers Res. Ther. 3(1):3; 2011.
              W. A.; Roberts, R. O.; Mielke, M. M.; Lowe, V. J.;   50.  Rovelet-Lecrux, A.; Frebourg, T.; Tuominen,
              Knopman, D. S.; Pankratz, V. S.; Machulda, M.   H.; Majamaa, K.; Campion, D.; Remes, A. M.
              M.. Association of elevated amyloid levels with   APP locus duplication in a Finnish family with
              cognition and biomarkers in cognitively nor-  dementia and intracerebral haemorrhage. J.
              mal people from the community. JAMA Neurol.   Neurol. Neurosurg. Psychiatry 78(10):1158-
              73(1):85-92; 2016.                           1159; 2007.
          43.  Pike, K. E.; Savage, G.; Villemagne, V. L.; Ng,   51.  Rowe, C. C.; Ellis, K. A.; Rimajova, M.; Bourgeat,
              S.; Moss, S. A.; Maruff, P.; Mathis, C. A.; Klunk,   P.; Pike, K. E.; Jones, G.; Fripp, J.; Tochon-Danguy,
              W. E.; Masters, C. L.; Rowe, C. C. Beta-amyloid   H.; Morandeau, L.; O’Keefe, G.; Price, R.; Raniga,
              imaging and memory in non-demented individ-  P.; Robins, P.; Acosta, O.; Lenzo, N.; Szoeke, C.;
              uals: evidence for preclinical Alzheimer’s disease.   Salvado, O.; Head, R.; Martins, R.; Masters, C.L.;
              Brain 130(Pt 11):2837-2844; 2007.            Ames, D.; Villemagne, V.L. Amyloid imaging
          44.  Price, J. C.; Klunk, W. E.; Lopresti, B. J.; Lu, X.;   results from the Australian Imaging, Biomarkers
   60   61   62   63   64   65   66   67   68   69   70